Assembly Biosciences, Inc. (ASMB)
Largest Insider Buys in Sector
ASMB Stock Price History Chart
ASMB Stock Performance
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Insider Activity of Assembly Biosciences, Inc.
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $1.14M and sold $139,156 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $711,484 and sold $159,949 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schornstein Alexander (10 percent owner) — $1.14M. GILEAD SCIENCES, INC. (10 percent owner) — $898.
The last purchase of 7,976 shares for transaction amount of $118,890 was made by Schornstein Alexander (10 percent owner) on 2024‑11‑25.
List of Insider Buy and Sell Transactions, Assembly Biosciences, Inc.
| 2024-11-25 | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | +10.16% | |||
| 2024-11-22 | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | +8.44% | |||
| 2024-11-18 | Sale | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | -1.96% | ||
| 2024-10-08 | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +15.46% | |||
| 2024-10-03 | Sale | CEO and President | 197 0.003% | $14.81 | $2,918 | +12.87% | ||
| 2024-10-03 | Sale | Chief Manufacturing Officer | 157 0.0024% | $14.81 | $2,325 | +12.87% | ||
| 2024-08-02 | Sale | CEO and President | 981 0.0158% | $14.23 | $13,962 | +14.14% | ||
| 2024-08-02 | Sale | Chief Manufacturing Officer | 785 0.0127% | $14.23 | $11,173 | +14.14% | ||
| 2024-07-05 | 10 percent owner | 4,438 0.063% | $12.52 | $55,564 | 0.00% | |||
| 2024-07-03 | 10 percent owner | 4,562 0.0636% | $12.29 | $56,067 | 0.00% | |||
| 2024-06-17 | 10 percent owner | 179,500 0.0002% | $0.00 | $180 | +5.87% | |||
| 2024-05-23 | Sale | director | 2,117 0.0389% | $14.93 | $31,615 | +4.61% | ||
| 2024-05-23 | Sale | CEO and President | 549 0.0101% | $14.93 | $8,199 | +4.61% | ||
| 2024-05-23 | Sale | Chief Manufacturing Officer | 172 0.0032% | $14.93 | $2,569 | +4.61% | ||
| 2024-05-23 | Sale | Principal Accounting Officer | 24 0.0004% | $14.93 | $358 | +4.61% | ||
| 2024-04-30 | Sale | CEO and President | 1,569 0.0292% | $12.71 | $19,937 | +24.73% | ||
| 2024-04-30 | Sale | Chief Manufacturing Officer | 1,255 0.0233% | $12.71 | $15,947 | +24.73% | ||
| 2024-04-01 | Sale | director | 1,206 0.0223% | $13.07 | $15,765 | +17.05% | ||
| 2024-04-01 | Sale | CEO and President | 354 0.0065% | $13.07 | $4,627 | +17.05% | ||
| 2024-04-01 | Sale | Chief Manufacturing Officer | 197 0.0036% | $13.07 | $2,575 | +17.05% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 1268972 19.964% | $15.21 | 1 | 0 | |
| Schornstein Alexander | 10 percent owner | 728113 11.455% | $15.21 | 9 | 0 | |
| McHutchison John G | director | 19104 0.3006% | $15.21 | 0 | 8 | |
| Okazaki Jason A | CEO and President | 14904 0.2345% | $15.21 | 0 | 13 | |
| White Nicole S | Chief Manufacturing Officer | 11871 0.1868% | $15.21 | 0 | 8 | |
| Bjorkquist Jeanette M | Principal Accounting Officer | 3142 0.0494% | $15.21 | 0 | 5 | |
| Small Derek A | CEO and President | 669291 10.5296% | $15.21 | 3 | 0 | <0.0001% |
| Lopatin Uri A | Chief Med. Off., VP Res. Dev. | 613611 9.6536% | $15.21 | 0 | 2 | |
| Delaney William E IV | Chief Scientific Officer | 150853 2.3733% | $15.21 | 0 | 8 | |
| Colonno Richard James | EVP & CSO, Virology Ops | 137009 2.1555% | $15.21 | 0 | 2 | |
| Samar Michael P. | Chief Financial Officer | 77228 1.215% | $15.21 | 0 | 2 | |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.9125% | $15.21 | 6 | 0 | +59.67% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.7391% | $15.21 | 3 | 0 | +85.85% |
| Stamm Luisa M | Chief Medical Officer | 40315 0.6343% | $15.21 | 0 | 2 | |
| Papkoff Jacqueline Sybil | SVP-CSO Microbiome | 37364 0.5878% | $15.21 | 0 | 3 | |
| RINGO WILLIAM R | director | 19465 0.3062% | $15.21 | 0 | 11 |
Institutional Investor Ownership
| The Vanguard Group | $2.61M | 3.21 | 196,368 | -91.61% | -$28.5M | <0.0001 | |
| Millennium Management LLC | $1.66M | 2.04 | 124,922 | -91.39% | -$17.62M | <0.01 | |
| BlackRock | $1.04M | 1.27 | 77,961 | -91.78% | -$11.57M | <0.0001 | |
| Geode Capital Management | $694,371.00 | 0.85 | 52,197 | -91.47% | -$7.45M | <0.0001 | |
| Acuitas Investments, LLC | $661,436.00 | 0.81 | 49,732 | -81.28% | -$2.87M | 0.35 | |
| Renaissance Technologies | $525,000.00 | 0.65 | 39,460 | -90.83% | -$5.2M | <0.01 | |
| Federated Hermes | $337,740.00 | 0.42 | 25,394 | -91.67% | -$3.72M | <0.01 | |
| Bridgeway Capital Management | $192,850.00 | 0.24 | 14,500 | -91.67% | -$2.12M | <0.01 | |
| State Street | $161,050.00 | 0.2 | 12,109 | -91.67% | -$1.77M | <0.0001 | |
| Fidelity Investments | $150,529.00 | 0.19 | 11,318 | -91.7% | -$1.66M | <0.0001 | |
| Northern Trust | $140,435.00 | 0.17 | 10,559 | -91.95% | -$1.6M | <0.0001 | |
| Tealwood Asset Management | $119,913.00 | 0.15 | 9,016 | -83.45% | -$604,459.41 | 0.03 | |
| Amundi | $105,760.00 | 0.13 | 7,934 | -91.67% | -$1.16M | <0.0001 | |
| Acadian Asset Management | $78,000.00 | 0.1 | 5,868 | -91.67% | -$858,053.17 | <0.0001 | |
| UBS | $43,026.00 | 0.05 | 3,235 | -86.61% | -$278,358.93 | <0.0001 | |
| Barclays | $40,000.00 | 0.05 | 2,994 | -91.67% | -$440,000.00 | <0.0001 | |
| Morgan Stanley | $32,877.00 | 0.04 | 2,472 | -91.94% | -$374,893.56 | <0.0001 | |
| Tower Research Capital | $11,398.00 | 0.01 | 857 | -93.4% | -$161,274.39 | <0.0001 | |
| RhumbLine Advisers | $2,646.00 | <0.01 | 199 | -91.72% | -$29,292.15 | <0.0001 | |
| EverSource Wealth Advisors | $686.00 | <0.01 | 55 | -91.72% | -$7,595.89 | <0.0001 | |
| Wells Fargo | $585.00 | <0.01 | 44 | -91.3% | -$6,142.50 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 79 | -85.53% | -$5,911.39 | <0.0001 | |
| JPMorgan Chase | $93.00 | <0.01 | 7 | -92.55% | -$1,155.86 | <0.0001 | |
| Qube Research & Technologies | $40.00 | <0.01 | 3 | -93.02% | -$533.33 | <0.0001 |